This content is not available in your region

Britain approves GSK-Vir antibody-based COVID-19 treatment

Access to the comments Comments
By Reuters
Britain approves GSK-Vir antibody-based COVID-19 treatment
Britain approves GSK-Vir antibody-based COVID-19 treatment   -   Copyright  Thomson Reuters 2021

– Britain’s drug regulator on Thursday approved GSK and Vir Biotechnology’s antibody based COVID-19 treatment, Xevudy, for people with mild-to-moderate COVID-19 who are at high risk of developing severe disease.

The approval comes as GSK separately announced the treatment has shown to work against the Omicron variant.